Advertisement

Topics

Royalty Pharma Company Profile

00:25 EDT 25th September 2017 | BioPortfolio

Since our inception in 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. By focusing on intellectual property - the key to premium pricing and profits in the pharmaceutical industry - Royalty Pharma has become the global leader in the acquisition of royalty interests. Royalty Pharma has assembled a well-diversified and well-balanced portfolio of royalties in leading biopharmaceutical products achieving rapid and profitable growth with a managed risk profile.
The origins of Royalty Pharma can be traced to the 1980s when certain members of Royalty Pharma’s Investment Committee and Management Team pioneered the use of royalty interests to fund the clinical development of several leading biotechnology products through “Research & Development Partnerships.” In 1993 and 1994, when these R&D partnerships started earning royalties, two product-specific "proof of principle" acquisition vehicles were established to acquire royalty interests in Neupogen® and ReoPro®. The success of those efforts led to the founding in 1996 of Royalty Pharma’s predecessors: Pharmaceutical Royalties, LLC (Delaware, USA) and Pharmaceutical Royalty Investments, Ltd. (Bermuda). Subsequently in 2003, Royalty Pharma was established as an Irish Unit Trust, to consolidate the operations of its predecessors and to facilitate a new business model for the Company.

Portfolio (view latest list)

Product           Indication Royalty - Seller
Approved / In Development 

Neupogen/Neulasta     Cancer, white blood cell stimulant MSK
Remicade - US & Int'l             Rheumatoid Arthritis (RA), UC, Crohn´s, PsA, AS, Psoriasis NYU
Humira               Rheumatoid Arthritis (RA), UC,  AstraZeneca
Rituxan - US               B-cell Lymphoma, RA, XOMA
Atripla/Truvada/Emtriva (3)               HIV/AIDS Emory
Thalomid             Multiple Myeloma Entre Med
Lyrica               Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Onset Seizures and Fibromyalgia Northwestern University
Prezista              HIV/AIDS PharmaCo
Letairis/Volibris               PAH PharmaCo
RotaTeq               Rotavirus Vaccine CHOP
Cubicin              cSSSI, Bacteremia, Endocarditis Not Disclosed
Savella                Fibromyalgia Cypress Bioscience
Myozyme/Lumizyme              Pompe Disease Academic Institution
Lexiscan             Pharmacological Stress Agent for MPI Not Disclosed
Januvia/Janumet              Diabetes Astellas
Onglyza/Kombiglyze             Diabetes Astellas
Galvus/Eucreas               Diabetes Astellas
Nesina               Diabetes Astellas
Tradjenta             Diabetes Astellas
TOBI           Anti-Infectives (cystic fibrosis) Inventor
Viviant               2nd gen. SERM: Osteoporosis Ligand
Cimzia               Rheumatoid Arthritis (RA), Crohn's Nektar Therapeutics
Mircera             Chronic Kidney Disease (CKD) Nektar Therapeutics
In Registration/Launch 
Vosaroxin          Acute Myeloid Leukemia (AML) Sunesis
Tecfidera           Psoriasis, Multiple Sclerosis Fumapharm AG Shareholders
Conbriza/Aprela (4)         2nd gen. SERM: Osteoporosis Ligand
Fablyn (4) 2nd gen.            SERM: Osteoporosis Ligand

Source: Royalty Pharma

Location

110 East 59th Street
33rd Floor Suite 3300
New York
New York
10022
United States of America

Contact

Phone: 212-883-0200
Fax: 212-883-2260
Email: mherman@royaltypharma.com


News Articles [2333 Associated News Articles listed on BioPortfolio]

Zealand Pharma Reports Royalty Revenue For The Second Quarter Of 2017

  Life Sciences Jobs   ...

Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners

EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has entered into a $100 million royalty-backed note agreement with HealthCa...

Adamas Pharma Signs $100 Million Royalty-Backed Note Agreement With

  Life Sciences Jobs   ...

Opiant Pharma Announces Additional $3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization

  Life Sciences Jobs   ...

LTL Pharma Succeeds Marketing Approval for "Nivadil® Tablets", "Solantal® Tablets" and "Lowgan® Tablets", and isTransferred Distribution Rights in Japan

Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Ph...

Dr. Robert S. Langer Joins HealthCare Royalty Partners Strategic Advisory Board

STAMFORD, Conn., Jan. 4, 2013 /PRNewswire/ -- HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced that Dr. Robert S. Langer, Institute Professor ...

HealthCare Royalty Partners Promotes Matthew Reber to Managing Director

STAMFORD, Conn., June 27, 2013 /PRNewswire/ -- HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced that Matthew Q. Reber has been promoted to Managing Dire...

Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 20102017 [Report Updated: 01092017] Prices from USD $1995

The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 20102017 report provides comprehensive understanding and unprecedented access to the royalty financing a...

Drugs and Medications [238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [32 Associated PubMed Articles listed on BioPortfolio]

The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.

In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innova...

Delivering advanced therapies: The big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...

Bioanalytical outsourcing: transitioning from Pharma to CRO.

AI-powered drug discovery captures pharma interest.

Clinical Trials Series - Large Pharma.

Clinical Trials [74 Associated Clinical Trials listed on BioPortfolio]

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Companies [743 Associated Companies listed on BioPortfolio]

DRUG ROYALTY CORPORATION INC

A pioneer in the field when launched in 1992, Drug Royalty was the first firm to provide royalty-based financing in the life sciences sector and the first to complete royalty transactions with invento...

Royalty Pharma

Since our inception in 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. By focusing on intellectual property - the key to premium pricing and profit...

Capital Royalty L.P.

Our diversified team of investment professionals is dedicated to meeting the specific needs of each client, and with our extensive experience in the healthcare and financial industries, Capital Royalt...

Drug Royalty

Drug Royalty is an innovative and profitable Canadian company involved in the international life science industry. Established in 1992, DRC was designed to participate in the growth from the global he...

DRI Capital Inc.

DRI is a pioneer and global leader in healthcare royalty investing and has completed transactions with large global pharmaceutical companies, biotechnology companies, universities...

More Information about "Royalty Pharma" on BioPortfolio

We have published hundreds of Royalty Pharma news stories on BioPortfolio along with dozens of Royalty Pharma Clinical Trials and PubMed Articles about Royalty Pharma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Royalty Pharma Companies in our database. You can also find out about relevant Royalty Pharma Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record